Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

Interaction of the phosphorylated DNA-binding domain in nuclear receptor CAR with its ligand-binding domain regulates CAR activation.

Shizu R, Min J, Sobhany M, Pedersen LC, Mutoh S, Negishi M.

J Biol Chem. 2018 Jan 5;293(1):333-344. doi: 10.1074/jbc.M117.806604. Epub 2017 Nov 13.

2.

Reversible Association of the Hemagglutinin Subcomplex, HA-33/HA-17 Trimer, with the Botulinum Toxin Complex.

Sagane Y, Mutoh S, Koizumi R, Suzuki T, Miyashita SI, Miyata K, Ohyama T, Niwa K, Watanabe T.

Protein J. 2017 Oct;36(5):417-424. doi: 10.1007/s10930-017-9733-y.

PMID:
28707196
3.

Isolation of botulinolysin, a thiol-activated hemolysin, from serotype D Clostridium botulinum: A species-specific gene duplication in Clostridia.

Suzuki T, Nagano T, Niwa K, Mutoh S, Uchino M, Tomizawa M, Sagane Y, Watanabe T.

Microbiol Res. 2016 Dec;193:20-29. doi: 10.1016/j.micres.2016.08.011. Epub 2016 Aug 23.

4.

Recent advances in immunotherapy for non-small-cell lung cancer.

Suzuki H, Owada Y, Watanabe Y, Inoue T, Fukuharav M, Yamaura T, Mutoh S, Okabe N, Yaginuma H, Hasegawa T, Yonechi A, Ohsugi J, Hoshino M, Higuchi M, Shio Y, Gotoh M.

Hum Vaccin Immunother. 2014;10(2):352-7. doi: 10.4161/hv.26919. Epub 2013 Nov 6. Review.

5.

Development of biotin-prototrophic and -hyperauxotrophic Corynebacterium glutamicum strains.

Ikeda M, Miyamoto A, Mutoh S, Kitano Y, Tajima M, Shirakura D, Takasaki M, Mitsuhashi S, Takeno S.

Appl Environ Microbiol. 2013 Aug;79(15):4586-94. doi: 10.1128/AEM.00828-13. Epub 2013 May 24.

6.

Phenobarbital indirectly activates the constitutive active androstane receptor (CAR) by inhibition of epidermal growth factor receptor signaling.

Mutoh S, Sobhany M, Moore R, Perera L, Pedersen L, Sueyoshi T, Negishi M.

Sci Signal. 2013 May 7;6(274):ra31. doi: 10.1126/scisignal.2003705.

7.

Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer.

Suzuki H, Fukuhara M, Yamaura T, Mutoh S, Okabe N, Yaginuma H, Hasegawa T, Yonechi A, Osugi J, Hoshino M, Kimura T, Higuchi M, Shio Y, Ise K, Takeda K, Gotoh M.

J Transl Med. 2013 Apr 11;11:97. doi: 10.1186/1479-5876-11-97.

8.

Pharmacological profile of FK881(ASP6537), a novel potent and selective cyclooxygenase-1 inhibitor.

Imanishi J, Morita Y, Yoshimi E, Kuroda K, Masunaga T, Yamagami K, Kuno M, Hamachi E, Aoki S, Takahashi F, Nakamura K, Miyata S, Ohkubo Y, Mutoh S.

Biochem Pharmacol. 2011 Oct 1;82(7):746-54. doi: 10.1016/j.bcp.2011.06.035. Epub 2011 Jul 2.

PMID:
21745460
9.

Prevention of renal interstitial fibrosis via histone deacetylase inhibition in rats with unilateral ureteral obstruction.

Kinugasa F, Noto T, Matsuoka H, Urano Y, Sudo Y, Takakura S, Mutoh S.

Transpl Immunol. 2010 May;23(1-2):18-23. doi: 10.1016/j.trim.2010.02.003. Epub 2010 Mar 3.

PMID:
20206695
10.

Dephosphorylation of threonine 38 is required for nuclear translocation and activation of human xenobiotic receptor CAR (NR1I3).

Mutoh S, Osabe M, Inoue K, Moore R, Pedersen L, Perera L, Rebolloso Y, Sueyoshi T, Negishi M.

J Biol Chem. 2009 Dec 11;284(50):34785-92. doi: 10.1074/jbc.M109.048108. Epub 2009 Oct 26.

11.

Constitutive increase in active GLP-1 levels by the DPP4 inhibitor ASP4000 on a new meal tolerance test in Zucker fatty rats.

Tanaka-Amino K, Hatakeyama Y, Takakura S, Mutoh S.

Pharmacol Res. 2009 Oct;60(4):264-9. doi: 10.1016/j.phrs.2009.03.018. Epub 2009 Apr 7.

PMID:
19520592
12.

Effect of the immunosuppressant histone deacetylase inhibitor FR276457 in a canine renal transplant model.

Kinugasa F, Nagatomi I, Nakanishi T, Noto T, Mori H, Matsuoka H, Sudo Y, Mutoh S.

Transpl Immunol. 2009 Sep;21(4):198-202. doi: 10.1016/j.trim.2009.04.006. Epub 2009 May 4.

PMID:
19409992
13.

ASP4000, a slow-binding dipeptidyl peptidase 4 inhibitor, has antihyperglycemic activity of long duration in Zucker fatty rats.

Tanaka-Amino K, Matsumoto K, Hatakeyama Y, Takakura S, Mutoh S.

Acta Diabetol. 2010 Mar;47(1):43-8. doi: 10.1007/s00592-009-0096-5. Epub 2009 Feb 24.

PMID:
19238312
14.

Tacrolimus (FK506) suppresses rt-PA-induced hemorrhagic transformation in a rat thrombotic ischemia stroke model.

Maeda M, Furuichi Y, Noto T, Matsuoka N, Mutoh S, Yoneda Y.

Brain Res. 2009 Feb 13;1254:99-108. doi: 10.1016/j.brainres.2008.11.080. Epub 2008 Dec 3.

PMID:
19101526
15.

Efficacy of oral treatment with tacrolimus in the renal transplant model in cynomolgus monkeys.

Kinugasa F, Nagatomi I, Ishikawa H, Nakanishi T, Maeda M, Hirose J, Fukahori H, Ooshima S, Noto T, Higashi Y, Seki N, Mutoh S.

J Pharmacol Sci. 2008 Dec;108(4):529-34.

16.

Thirteen-month inhibition of aldose reductase by zenarestat prevents morphological abnormalities in the dorsal root ganglia of streptozotocin-induced diabetic rats.

Shimoshige Y, Minoura K, Matsuoka N, Takakura S, Mutoh S, Kamijo M.

Brain Res. 2009 Jan 9;1247:182-7. doi: 10.1016/j.brainres.2008.10.018. Epub 2008 Nov 1.

PMID:
18992730
17.

FK1706, a novel non-immunosuppressive immunophilin ligand, modifies the course of painful diabetic neuropathy.

Yamazaki S, Yamaji T, Murai N, Yamamoto H, Price RD, Matsuoka N, Mutoh S.

Neuropharmacology. 2008 Dec;55(7):1226-30. doi: 10.1016/j.neuropharm.2008.07.048. Epub 2008 Aug 8.

PMID:
18760290
18.

Effect of a new immunosuppressant histon deacetylase (HDAC) inhibitor FR276457 in a rat cardiac transplant model.

Kinugasa F, Yamada T, Noto T, Matsuoka H, Mori H, Sudo Y, Mutoh S.

Biol Pharm Bull. 2008 Sep;31(9):1723-6.

19.

Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds.

Maki K, Matsumoto S, Watabe E, Iguchi Y, Tomishima M, Ohki H, Yamada A, Ikeda F, Tawara S, Mutoh S.

Microbiol Immunol. 2008 Aug;52(8):383-91. doi: 10.1111/j.1348-0421.2008.00053.x.

20.

FK1706, a novel non-immunosuppressant neurophilin ligand, ameliorates motor dysfunction following spinal cord injury through its neuroregenerative action.

Yamaji T, Yamazaki S, Li J, Price RD, Matsuoka N, Mutoh S.

Eur J Pharmacol. 2008 Sep 4;591(1-3):147-52. doi: 10.1016/j.ejphar.2008.06.064. Epub 2008 Jun 20.

PMID:
18602914
21.

Novel method for selecting immunosuppressive histone deacetylase (HDAC) inhibitors with minimal thrombocytopenia.

Matsuoka H, Fujimura T, Unami A, Yamada T, Noto T, Takata Y, Yoshizawa K, Mori H, Aramori I, Mutoh S.

Biol Pharm Bull. 2008 Feb;31(2):305-8.

22.

Direct comparison of the pharmacodynamics of four antifungal drugs in a mouse model of disseminated candidiasis using microbiological assays of serum drug concentrations.

Maki K, Holmes AR, Watabe E, Iguchi Y, Matsumoto S, Ikeda F, Tawara S, Mutoh S.

Microbiol Immunol. 2007;51(11):1053-9.

23.

Mechanism of HDAC inhibitor FR235222-mediated IL-2 transcriptional repression in Jurkat cells.

Matsuoka H, Fujimura T, Mori H, Aramori I, Mutoh S.

Int Immunopharmacol. 2007 Nov;7(11):1422-32. Epub 2007 Jul 17.

PMID:
17761346
24.

Mechanisms of HDAC inhibitor-induced thrombocytopenia.

Matsuoka H, Unami A, Fujimura T, Noto T, Takata Y, Yoshizawa K, Mori H, Aramori I, Mutoh S.

Eur J Pharmacol. 2007 Oct 1;571(2-3):88-96. Epub 2007 Jun 26.

PMID:
17628529
25.

Disruption of HDAC4/N-CoR complex by histone deacetylase inhibitors leads to inhibition of IL-2 gene expression.

Matsuoka H, Fujimura T, Hayashi M, Matsuda K, Ishii Y, Aramori I, Mutoh S.

Biochem Pharmacol. 2007 Aug 1;74(3):465-76. Epub 2007 May 6.

PMID:
17559812
26.

Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.

Minoura H, Takeshita S, Kimura C, Hirosumi J, Takakura S, Kawamura I, Seki J, Manda T, Mutoh S.

Diabetes Obes Metab. 2007 May;9(3):369-78.

PMID:
17391165
27.

Tacrolimus (FK506) limits accumulation of granulocytes and platelets and protects against brain damage after transient focal cerebral ischemia in rat.

Noto T, Furuichi Y, Ishiye M, Matsuoka N, Aramori I, Mutoh S, Yanagihara T.

Biol Pharm Bull. 2007 Feb;30(2):313-7.

28.

Therapeutic time window of tacrolimus (FK506) in a nonhuman primate stroke model: comparison with tissue plasminogen activator.

Furuichi Y, Maeda M, Matsuoka N, Mutoh S, Yanagihara T.

Exp Neurol. 2007 Mar;204(1):138-46. Epub 2006 Dec 13.

PMID:
17169359
29.

Temporal and topographic profiles of tissue hypoxia following transient focal cerebral ischemia in rats.

Noto T, Furuichi Y, Ishiye M, Matsuoka N, Aramori I, Mutoh S, Yanagihara T, Manabe N.

J Vet Med Sci. 2006 Aug;68(8):803-7.

30.

Tacrolimus (FK506) attenuates biphasic cytochrome c release and Bad phosphorylation following transient cerebral ischemia in mice.

Li JY, Furuichi Y, Matsuoka N, Mutoh S, Yanagihara T.

Neuroscience. 2006 Oct 27;142(3):789-97. Epub 2006 Aug 28.

PMID:
16935431
31.

Quantitative detection of gene expression and toxin complex produced by Clostridium botulinum serotype D strain 4947.

Kouguchi H, Suzuki T, Hasegawa K, Mutoh S, Watanabe T, Niwa K, Yoneyama T, Katoh Y, Ohyama T.

J Microbiol Methods. 2006 Dec;67(3):416-23. Epub 2006 May 24.

PMID:
16725219
32.

A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.

Fujimura T, Kimura C, Oe T, Takata Y, Sakuma H, Aramori I, Mutoh S.

J Pharmacol Exp Ther. 2006 Aug;318(2):863-71. Epub 2006 May 8.

PMID:
16682454
33.

Inhibitory effect of zacopride on Cisplatin-induced delayed emesis in ferrets.

Yamakuni H, Nakayama H, Matsui S, Imazumi K, Matsuo M, Mutoh S.

J Pharmacol Sci. 2006 May;101(1):99-102. Epub 2006 Apr 29.

34.

Determination of antifungal activities in serum samples from mice treated with different antifungal drugs allows detection of an active metabolite of itraconazole.

Maki K, Watabe E, Iguchi Y, Nakamura H, Tomishima M, Ohki H, Yamada A, Matsumoto S, Ikeda F, Tawara S, Mutoh S.

Microbiol Immunol. 2006;50(4):281-92.

35.
36.

FR177391, a new anti-hyperlipidemic agent from Serratia. II. Pharmacological activity of FR177391.

Inami M, Kawamura I, Tsujimoto S, Yasuno T, Lacey E, Hirosumi J, Takakura S, Nishigaki F, Naoe Y, Manda T, Mutoh S.

J Antibiot (Tokyo). 2005 Oct;58(10):640-7.

PMID:
16392680
37.

Four molecules of the 33 kDa haemagglutinin component of the Clostridium botulinum serotype C and D toxin complexes are required to aggregate erythrocytes.

Mutoh S, Suzuki T, Hasegawa K, Nakazawa Y, Kouguchi H, Sagane Y, Niwa K, Watanabe T, Ohyama T.

Microbiology. 2005 Dec;151(Pt 12):3847-58.

PMID:
16339931
38.

FK962, a novel enhancer of somatostatin release, exerts cognitive-enhancing actions in rats.

Tokita K, Inoue T, Yamazaki S, Wang F, Yamaji T, Matsuoka N, Mutoh S.

Eur J Pharmacol. 2005 Dec 19;527(1-3):111-20.

PMID:
16325809
39.

FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators.

Fujimura T, Sakuma H, Konishi S, Oe T, Hosogai N, Kimura C, Aramori I, Mutoh S.

J Pharmacol Sci. 2005 Dec;99(4):342-52. Epub 2005 Nov 26.

40.

Prohemorrhagic and bleeding time activities of recombinant tissue plasminogen activator, heparin, aspirin, and a glycoprotein IIb/IIIa antagonist.

Mihara K, Aoki T, Moriguchi A, Maeda M, Furuichi Y, Matsuoka N, Mutoh S.

J Neurotrauma. 2005 Nov;22(11):1362-73.

PMID:
16305324
41.

Association of the antagonism of von Willebrand factor but not fibrinogen by platelet alphaIIbbeta3 antagonists with prolongation of bleeding time.

Aoki T, Tomiyama Y, Honda S, Mihara K, Yamanaka T, Okubo M, Moriguchi A, Mutoh S.

J Thromb Haemost. 2005 Oct;3(10):2307-14. Epub 2005 Sep 7.

42.

Monoclonal antibody 1-22-3-induced glomerulonephritis in uninephrectomized rats as a model of progressive renal failure.

Tomita M, Sogabe H, Nakazato S, Nakatsuji S, Noto T, Hamada K, Kawachi H, Shimizu F, Matsuo M, Mutoh S.

Nephrol Dial Transplant. 2005 Nov;20(11):2358-67. Epub 2005 Aug 9.

PMID:
16091375
43.

Antiemetic activity of FK1052, a 5-HT3- and 5-HT4-receptor antagonist, in Suncus murinus and ferrets.

Nakayama H, Yamakuni H, Higaki M, Ishikawa H, Imazumi K, Matsuo M, Mutoh S.

J Pharmacol Sci. 2005 Aug;98(4):396-403. Epub 2005 Jul 29.

44.

Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.

Minoura H, Takeshita S, Yamamoto T, Mabuchi M, Hirosumi J, Takakura S, Kawamura I, Seki J, Manda T, Ita M, Mutoh S.

Eur J Pharmacol. 2005 Sep 5;519(1-2):182-90.

PMID:
16039648
45.

FK506 inhibits prostaglandin E2 production from synovial cells by suppressing peripheral blood mononuclear cells.

Sasakawa T, Sasakawa Y, Ohkubo Y, Mutoh S.

Int Immunopharmacol. 2005 Jul;5(7-8):1291-7. Epub 2005 Apr 21.

PMID:
15914333
46.

Tacrolimus (FK506) has protective actions against murine bleomycin-induced acute lung injuries.

Koshika T, Hirayama Y, Ohkubo Y, Mutoh S, Ishizaka A.

Eur J Pharmacol. 2005 May 16;515(1-3):169-78.

PMID:
15894307
47.

Characterization of the interaction between subunits of the botulinum toxin complex produced by serotype D through tryptic susceptibility of the isolated components and complex forms.

Suzuki T, Watanabe T, Mutoh S, Hasegawa K, Kouguchi H, Sagane Y, Fujinaga Y, Oguma K, Ohyama T.

Microbiology. 2005 May;151(Pt 5):1475-83.

PMID:
15870457
48.

FK506 aerosol locally inhibits antigen-induced airway inflammation in Guinea pigs.

Morishita Y, Hirayama Y, Miyayasu K, Tabata K, Kawamura A, Ohkubo Y, Mutoh S.

Int Arch Allergy Immunol. 2005 Apr;136(4):372-8. Epub 2005 Mar 2.

PMID:
15746557
49.

Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors.

Iwashita A, Hattori K, Yamamoto H, Ishida J, Kido Y, Kamijo K, Murano K, Miyake H, Kinoshita T, Warizaya M, Ohkubo M, Matsuoka N, Mutoh S.

FEBS Lett. 2005 Feb 28;579(6):1389-93.

50.

A review of the action of tacrolimus (FK506) on experimental models of rheumatoid arthritis.

Miyata S, Ohkubo Y, Mutoh S.

Inflamm Res. 2005 Jan;54(1):1-9. Review.

PMID:
15723198

Supplemental Content

Support Center